Loading
A phase 3 trial testing Rocbrutinib in mantle cell lymphoma, now recruiting.
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma is a phase 3 interventional study registered as NCT07377578, led by Guangzhou Lupeng Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Open-label, Multicenter, Phase III Clinical Study Comparing Rocbrutinib Monotherapy Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (PRIME Study). Planned enrolment is 394 participants (estimated). The study started in 2026-02-05 and primary completion is expected in 2031-05-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rocbrutinib, Lupeng Pharmaceuticals, Mantle cell lymphoma.
Shares Rocbrutinib, Lupeng Pharmaceuticals, Mantle cell lymphoma.
Shares Rocbrutinib, Lupeng Pharmaceuticals.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/